ArticleFrontiers in microbiology2026
Development of a rapid, sensitive and visual reverse transcription recombinase-aided amplification coupled with lateral flow dipstick assay for influenza B virus detection.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Influenza B virus (IBV) is a major etiological agent of seasonal influenza, imposing a significant global health burden. Rapid and accurate detection is crucial for epidemic control, but conventional methods are limited by complex equipment or long turnaround times. Methods: Herein, we developed a reverse transcription recombinase-aided amplification assay combined with lateral flow dipstick (RT-RAA-LFD) for specific IBV detection, targeting the conserved Results: Following primer screening, the optimal primer pair F2/R4 was identified. The assay was optimized to react at 39°C for 20 min with a detection volume of 15 μL. Analytical validation demonstrated high sensitivity (50 copies/mL) and no nonspecific cross-reactivity with other common respiratory viruses, including influenza A virus, SARS-CoV-2, parainfluenza virus and adenovirus. Clinical performance evaluation revealed 100% concordance with the gold standard PCR assay. Discussion: Collectively, the established RT-RAA-LFD assay is rapid, specific, sensitive and easy to operate without relying on sophisticated instruments, making it a promising tool for point-of-care testing (POCT) and field surveillance of IBV infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.